Heart:冠状动脉分叉病变是选择PS还是TS?

2017-03-19 MedSci MedSci原创

由此可见,相比于冠状动脉分叉病变的TS治疗策略,PS可能与长期死亡率益处有关。

冠状动脉分叉病变的最佳介入技术是值得商榷的。对于分叉病变进行Provisional支架置入术(PS)与双支架(TS)策略的长期临床结局比较的数据较为稀缺。近日,在心脏病领域权威杂志Heart上发表了一篇荟萃分析文章,研究人员对这些随机对照试验(RCT)进行了荟萃分析,以探究两种策略的长期临床结局。

研究人员通过对电子数据库进行检索,截止日期到2016年8月,查找比较PS和TS治疗分叉病变,并且报告了随访1年或更长时间结局的随机对照试验。研究人员通过随机效应模型来计算感兴趣结果的风险比(RRs)。

研究人员纳入了8个随机对照试验共有2778例报告了长期临床结局的患者。平均随访了3±1.6年,PS与较低的全因死亡率风险相关(RR=0.66;95% 可信区间为0.45-0.98;P=0.04),与TS治疗分叉病变相比较。在主要心脏不良事件(MACE)、心肌梗死(MI)、靶病变血运重建(TLR)或支架血栓(ST)上PS与TS组相比无显著性差异。在敏感性分析中限定随访时间≥3年的试验,PS与较低的全因死亡率(RR=0.57;95% 可信区间为0.36-0.88;P=0.01)、MACE(RR=0.71;95% 可信区间为0.52-0.97;P=0.03)和心肌梗死(RR=0.45;95% 可信区间为0.21-0.96;P=0.04)风险相关,相比于TS,在平均随访4.6±0.7年中。两种治疗策略的TLR和ST的风险仍然类似(RR=0.81;95% 可信区间为0.57-1.15;P=0.24;和RR=0.75;95% 可信区间为0.19-2.84;P=0.67)。Meta回归分析发现急性冠脉综合征患者进行PS发生MACE的风险增加(P=0.05)。

由此可见,相比于冠状动脉分叉病变的TS治疗策略,PS可能与长期死亡率益处有关。

原始出处:

Ramez Nairooz,et al. Long-term outcomes of provisional stenting compared with a two-stent strategy for bifurcation lesions: a meta-analysis of randomised trials. Heart. 2017. http://dx.doi.org/10.1136/heartjnl-2016-310929

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356192, encodeId=6e811356192b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557357, encodeId=f1ca155e3572f, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562458, encodeId=f65715624583a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=)]
    2017-03-21 docwu2019
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356192, encodeId=6e811356192b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557357, encodeId=f1ca155e3572f, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562458, encodeId=f65715624583a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356192, encodeId=6e811356192b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557357, encodeId=f1ca155e3572f, content=<a href='/topic/show?id=dd173153617' target=_blank style='color:#2F92EE;'>#分叉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31536, encryptionId=dd173153617, topicName=分叉病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e47e14911964, createdName=sjzlzc012, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562458, encodeId=f65715624583a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 21 03:46:00 CST 2017, time=2017-03-21, status=1, ipAttribution=)]
    2017-03-21 slcumt

相关资讯

Catheter Cardiovasc Interv:生物可吸收支架植入术可能作为分叉病变的治疗策略

目的:本研究的目的是调研以生物可吸收支架(BRS)的临时支架(PS) vs双支架(DS)策略用于冠状动脉分叉病变治疗的临床结果。相关以生物可吸收支架植入治疗分叉病变的临床结果数据较为有限。方法:在2012年到2014年间,对132例生物可吸收支架BRS治疗分叉病变的病历进行了分析。在132例分叉病变中,10例病变没有用交叉支架治疗。99例病变(81%)用临时支架PS治疗策略,23例病变(

JACC:PCI术后合并分叉病变,常规支架与专用分叉支架如何选择?

有症状的冠心病患者,在行径皮冠状动脉介入术后,经常会发生分叉病变,其比率接近15%-20%。尽管支架技术目前已经有了很大的进展,然而,分叉病变对于心脏疾病的介入治疗仍然是一项重大的挑战,其与围手术期心肌梗死,支架内血栓,远期再狭窄有着密切的联系。虽然已经有了很多对应的技术与治疗策略,目前的主流方案仍然是:主干病变首先治疗,分叉病变需要时再进行治疗。几项小的随机研究显示,对于

CIT 2014:冠脉分叉病变RESOLVE评分

研究背景 冠状动脉分叉病变始终是经皮冠状动脉介入治疗(PCI)中的一个难题,也是PCI中的常见病变,约占PCI总量的15%~20%。目前分叉病变介入治疗策略主要有选择性双支架技术和临时决定的双支架技术。选择性双支架技术如Crush等技术可有效保证分支血管通畅,但操作复杂且费用高;临时决定的双支架技术操作简单,但易使分支闭塞,进而导致患者心肌缺血、急性心肌梗死甚至死亡。分叉病变的介入治疗策